Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.

Oncogene·2026

Same author

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.

Nature communications·2026

Same author

TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion.

Cancer gene therapy·2026

Same author

Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers.

ACS medicinal chemistry letters·2026

Same author

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Cell death & disease·2025

Same author

Confirmation by conformation: rescue of mutant p53 in AML.

Blood·2025

Same journal

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Same journal

Patient value over patent value: the mandate for open-source oncology.

Nature reviews. Clinical oncology·2026

Same journal

Cancer burden and control in China: landscape, trends and challenges.

Nature reviews. Clinical oncology·2026

Same journal

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026

Same journal

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026

Same journal

Teclistamab monotherapy improves survival in RRMM.

Nature reviews. Clinical oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Translating p53 into the clinic.

Chit Fang Cheok¹, Chandra S Verma, José Baselga

¹p53 Laboratory, A*STAR, Singapore.

Nature Reviews. Clinical Oncology

|October 27, 2010

Summary

This summary is machine-generated.

Targeting the TP53 gene and its associated p53 pathway is a key strategy in cancer therapy. Various approaches, including gene therapy and MDM2 inhibitors, are being investigated in clinical trials.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Experiment Videos

Last Updated: Jun 7, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

TP53 gene mutations occur in 50% of cancers, with the p53 pathway often impaired in the remaining 50%.
Targeted cancer therapies are advancing, with a focus on exploiting the p53 system.

Purpose of the Study:

To review current and future p53-based cancer therapies.
To discuss the rationale and ongoing clinical trials for p53-targeting agents.

Main Methods:

Review of ongoing clinical trials for TP53-based therapies.
Discussion of various therapeutic strategies including gene therapy, vaccines, protein-drug conjugates, MDM2 inhibitors, and mutant TP53 reactivators.

Main Results:

TP53 gene therapy is the only approved p53-based treatment.
p53-based vaccines, protein-drug conjugates, and MDM2 inhibitors are in clinical trials.
The first agent to restore mutant TP53 function has entered clinical trials.

Conclusions:

The p53 pathway is a significant target for novel cancer therapies.
Diverse therapeutic strategies targeting TP53 are under active investigation and development.